Company / Accounts Receivable
Neurocrine Biosciences Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$686.8M
FY2025
5-year range
$185.5M / $686.8M
FY2021-FY2025
Trend
+43.4%
vs FY2024
Sector context
#22 of 115
Health Care
What the data says
Neurocrine Biosciences's accounts receivable of $687M is higher than 81% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 9 consecutive years, from $0 in FY2016 to $687M in FY2025.
Based on SEC 10-K filings.
$687M in FY2025 with a 5-year CAGR of +34.3%. Top quartile in the Health Care sector.
Improved from $439M to $687M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +25.2%
- 5-Year CAGR
- +34.3%
- 10-Year CAGR
- -
Sector benchmark
-38.6% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's accounts receivable has grown for 8 consecutive years.
- 5-year CAGR of +34.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 43.4% year-over-year.
- Ranks #22 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $686.8M | +43.4% |
| FY2024 | $479.1M | +9.1% |
| FY2023 | $439.3M | +25.5% |
| FY2022 | $350.0M | +88.7% |
| FY2021 | $185.5M | +18.1% |
| FY2020 | $157.1M | +24.1% |
| FY2019 | $126.6M | +120.5% |
| FY2018 | $57.4M | +84.4% |
| FY2017 | $31.1M | - |
| FY2016 | $0 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026